27.Peters SAE, Colantonio LD, Zhao H, Bittner V, Dai Y, Farkouh ME, et al. Sex differences in high-intensity statin use following myocardial infarction in the United States. J Am Coll Cardiol 2018;71:1729–37. https://doi.org/10.1016/j.jacc...
参考文献: [1] Michael O'Riordan. Good News and Bad for High-Intensity Statin Use in ASCVD. tctMD. MAY 05, 2022. [2] Nelson A, Haynes K, Shambhu S, et al. High-Intensity Statin Use Among Patients With Atherosclerosis in the...
参考文献: [1] Michael O'Riordan. Good News and Bad for High-Intensity Statin Use in ASCVD. tctMD. MAY 05, 2022. [2] Nelson A, Haynes K, Shambhu S, et al. High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.. J Am Coll Cardiol. 2022 May, 79 (18):1802–18...
Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial https://pubmed.ncbi.nlm.nih.gov/36529993/
(本文由北京大学第三医院药剂科翟所迪教授及其团队选题并审校,环球医学资讯编辑完成。) 参考资料: J Am Coll Cardiol. 2022 May 10;79(18):1802-1813 High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S https://pubmed.ncbi.nlm.nih.gov/35512860/...
Abstract 4116093: High Intensity Statin Use Improved ASCVD Outcomes in Patients with Severe Hyperlipidemia in a Primary Prevention Cohortdoi:10.1161/circ.150.suppl_1.4116093HyperlipidemiaStatinsOutcomesBackground:High intensity statin therapy is currently recommended for primary prevention of ASCVD in patients ...
[1] Michael O'Riordan. Good News and Bad for High-Intensity Statin Use in ASCVD. tctMD. MAY 05, 2022. [2] Nelson A, Haynes K, Shambhu S, et al. High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.. J Am Coll Cardiol. 2022 May, 79 (18):1802–1813....
13. Robinson J G, Nedergaard B S, Rogers W J, et al. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial[J]. JAMA , 2014, 311(18): 1870-1883. ...
Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients. Int J Cardiol. 2021;332:22–8. This study showed that among patients with a history of MI, prescription of high-...
The 2019 ACC/AHA guidelines recommend either a high-intensity or moderate-intensity statin regimen in patients who have an elevated ASCVD risk (≥ 5-7.5%) for primary prevention of cardiovascular disease. The recommended doses for each of these regimens are shown below: ...